Kristi Rosa

In an effort to enable healthcare providers and patients to make more informed medical decisions, the FDA has proposed amendments to key policies to modernize breast cancer screening and improve mammography services.

The Health and Human Services Secretary has announced Norman E. Sharpless, MD, will serve as acting commissioner of the FDA following the resignation of Scott Gottlieb, MD, in April 2019.

Jeff Sharman, MD, discusses the implications of real-world ibrutinib findings in mantle cell lymphoma and underscored the need for the development of more effective treatments for this patient population.

Eytan M. Stein, MD, sheds light on the current treatment landscape of AML and underscored the importance of molecular monitoring. In addition, he highlights where the field of AML is headed.

Ruben A. Mesa, MD, discusses the evolving role of interferon in the treatment of patients with MPNs, highlights recent treatment advances, and shares insight on the future of treatment for these patients.

To date, there is no national Medicare policy in place to provide coverage for CAR T-cell therapies, which have been proven to be a successful treatment for certain patients with relapsed/refractory cancers. Now, the Centers for Medicare & Medicaid Services has proposed to cover CAR T-cell therapies approved by the FDA under “Coverage with Evidence Development."

A small subset of patients with colorectal cancer benefited from the combination of nivolumab (Opdivo) and pixatimod (PG545), according to early results from a phase Ib trial.

Data from a retrospective study suggests an adjuvant gastrointestinal-based chemotherapy regimen is more beneficial than one that is gynecologic-based in patients with mucinous ovarian cancer, said Katherine C. Kurnit, MD.

In recognition of the many advancements that have been made in the past year toward developing new therapies for patients with difficult-to-treat, rare cancers, ASCO has chosen progress in treating rare cancers as its Advance of the Year.

In an interview with <em>Targeted Oncology</em>&nbsp;during the 2019 SGO Annual Winter Meeting, Shannon Westin, MD, discussed the advances seen with PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.

Robert Coleman, MD,&nbsp;highlights recent advances made in gynecologic cancers and provide insight into ongoing research to move the needle forward.

A partial clinical hold has been placed on the&nbsp;phase III AIM2CERV trial by the FDA, Advaxis, Inc. has announced.¹ The trial is evaluating the use of the investigational immunotherapy agent axalimogene filolisbac in high-risk locally advanced cervical cancer.

An ongoing randomized phase III clinical trial is investigating the safety and efficacy of&nbsp;atezolizumab compared with placebo as an adjuvant treatment after definitive local therapy in patients with high-risk, locally advanced squamous cell carcinoma of the head and neck.

In a merger agreement announced today,&nbsp;Bristol-Myers Squibb will be acquiring Celgene Corporation in a $74 billion deal to be paid with a combination of cash and stocks.

Novel immunomodulatory agent pixatimod combined with nivolumab, a PD-1 inhibitor, may benefit patients with advanced bowel cancers, including a small subset of those with colorectal cancer considered to be microsatellite stable.

CT-P6 received approval from the FDA as a biosimilar for&nbsp;trastuzumab for the treatment of patients with HER2-overexpressing breast cancer.

The PD-1 inhibitor cemiplimab in combination with radiotherapy, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor did not demonstrate efficacy superior to other PD-1 inhibitor monotherapies in patients with recurrent or metastatic head and neck squamous cell carcinoma, according to results from a phase I expansion cohort that were presented at the 2018 ESMO Congress.

A supplemental new drug application (sNDA)&nbsp;for avatrombopag (Doptelet) as a treatment for patients with chronic immune thrombocytopenia (ITP) who have had an inadequate response to prior treatment has been accepted for review by the FDA.